TGFB1 and osteogenesis imperfecta: Interestingly, in several bone pathologies, including the brittle bone disease Osteogenesis Imperfecta (OI), excessive TGF-β signalling has been reported in bone cells and in the skeleton of mice with OI, and TGF-β neutralizing antibody treatment rescued the bone phenotype in the mice [47–49].